Seasonal variation in Tp53 R249S-mutated serum DNA with aflatoxin exposure and hepatitis B virus infection

Environmental Health Perspectives

Volumn 119, Issue 11, 2011, Pages 1635-1640

  Villar, Stéphanie ^a   Le Roux Goglin, Emilie ^a   Gouas, Doriane A ^a   Plymoth, Amelie ^a,h   Ferro, Gilles ^a,i   Boniol, Mathieu ^b,i   Lereau, Myriam ^a   Bah, Ebrima ^b   Hall, Andrew J ^c   Wild, Christopher P ^a   Mendy, Maimuna ^d   Norder, Helene ^e   van der Sande, Marianne ^f   Whittle, Hilton ^b   Friesen, Marlin D ^g   Groopman, John D ^g   Hainaut, Pierre ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b Gambia Hepatitis Intervention Study   (Gambia)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^e SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^f NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^g JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^h KAROLINSKA INSTITUTE   (Sweden)

ⁱ INTERNATIONAL PREVENTION RESEARCH INSTITUTE   (France)

Author keywords

1762 T 1764 A; Circulating DNA; Mycotoxin; Seasonality; TP53 mutation

Indexed keywords

AFLATOXIN B1; DNA; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; PROTEIN P53; VIRUS DNA;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER RISK; CHILD; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIETARY INTAKE; FEMALE; GAMBIA; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HEALTH SURVEY; HEPATITIS B; HEPATITIS B VIRUS; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; S GENE; SCHOOL CHILD; SEASONAL VARIATION; SEQUENCE ANALYSIS; TP53 GENE; TUMOR GENE; VIRUS GENE; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION;

ADULT; AFLATOXINS; AGED; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DNA, VIRAL; FEMALE; GAMBIA; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INFANT; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RISK FACTORS; SEASONS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TUMOR SUPPRESSOR PROTEIN P53;

HEPATITIS B VIRUS;

EID: 80455173434     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.1103539     Document Type: Article

References (40)

1. Arbuthnot P, Kew M. 2001. Hepatitis B virus and hepatocellular carcinoma. Int J Exp Pathol 82:77-100.
2. Bah E, Parkin DM, Hall AJ, Jack AD, Whittle H. 2001. Cancer in the Gambia: 1988-97. Br J Cancer 84:1207-1214.
3. Baptista M, Kramvis A, Kew MC. 1999. High prevalence of 1762T 1764A mutations in the basic core promoter of hepatitis B virus isolated from black Africans with hepatocellular carcinoma compared with asymptomatic carriers. Hepatology 29:946-953.
4. Besaratinia A, Kim SI, Hainaut P, Pfeifer GP. 2009. In vitro recapitulating of TP53 mutagenesis in hepatocellular carcinoma associated with dietary aflatoxin B1 exposure. Gastroenterology 137:1127-1137.
5. Chan KC, Leung SF, Yeung SW, Chan AT, Lo YM. 2008. Persistent aberrations in circulating DNA integrity after radiotherapy are associated with poor prognosis in nasopharyngeal carcinoma patients. Clin Cancer Res 14:4141-4145.
6. Department of Agricultural Services, the Gambia. 2008. Profile of Achievements, 1994-2001. Available: http://www.statehouse.gm/agriculture/achievements.html [accessed 11 July 2011].
7. Gormally E, Caboux E, Vineis P, Hainaut P. 2007. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res 635:105-117.
8. Gormally E, Vineis P, Matullo G, Veglia F, Caboux E, Le Roux E, et al. 2006. TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study. Cancer Res 66:6871-6876.
9. Gouas D, Shi H, Hainaut P. 2009. The aflatoxin-induced TP53 mutation at codon 249 (R249S): biomarker of exposure, early detection and target for therapy. Cancer Lett 286:29-37.
10. Hagiwara N, Mechanic LE, Trivers GE, Cawley HL, Taga M, Bowman ED, et al. 2006. Quantitative detection of p53 mutations in plasma DNA from tobacco smokers. Cancer Res 66:8309-8317.
11. Hou J, Lau GK, Cheng J, Cheng CC, Luo K, Carman WF. 1999. T1762/A1764 variants of the basal core promoter of hepatitis B virus; serological and clinical correlations in Chinese patients. Liver 19:411-417.
12. Hussain M, Chu CJ, Sablon E, Lok ASF. 2003. Rapid and sensitive assays for determination of hepatitis B virus (HBV) genotypes and detection of HBV precore and core promoter variants. J Clin Microbiol 41:3699-3705.
13. IARC (International Agency for Research on Cancer). 1994. Hepatitis Viruses. IARC Monogr Eval Carcinog Risk Hum 59:1-255.
14. IARC (International Agency for Research on Cancer). 2002. Some Traditional Herbal Medicines, Some Mycotoxins, Naphthalene and Styrene. IARC Monogr Eval Carcinog Risk Hum 82:1-556.
15. Jackson PE, Kuang SY, Wang JB, Strickland PT, Muñoz A, Kensler TW, et al. 2003. Prospective detection of codon 249 mutations in plasma of hepatocellular carcinoma patients. Carcinogenesis 24:1657-1663.
16. Kew MC. 2003. Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis. Liver Int 23:405-409.
17. Kirk GD, Bah E, Montesano R. 2006. Molecular epidemiology of human liver cancer: insights into etiology, pathogenesis and prevention from the Gambia, West Africa. Carcinogenesis 27:2070-2082.
18. Kirk GD, Lesi OA, Mendy M, Szymañska K, Whittle H, Goedert JJ, et al. 2005. 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene 24:5858-5867.
19. Kramvis A, Kew M, François G. 2005. Hepatitis B virus genotypes. Vaccine 23:2409-2423.
20. Kuang SY, Jackson PE, Wang JB, Lu PX, Muñoz A, Qian GS, et al. 2004. Specific mutations of hepatitis B virus in plasma predict liver cancer development. Proc Natl Acad Sci USA 101:3575-3580.
21. Kuang SY, Lekawanvijit S, Maneekarn N, Thongsawat S, Brodovicz K, Nelson K, et al. 2005. Hepatitis B 1762T/1764A mutations, hepatitis C infection, and codon 249 p53 mutations in hepatocellular carcinomas from Thailand. Cancer Epidemiol Biomarkers Prev 14:380-384.
22. Lleonart ME, Kirk GD, Villar S, Lesi OA, Dasgupta A, Goedert JJ, et al. 2005. Quantitative analysis of plasma TP53 249Ser-mutated DNA by electrospray ionization mass spectrometry. Cancer Epidemiol Biomarkers Prev 14:2956-2962.
23. Lo YM, Zhang J, Leung TN, Lau TK, Chang AM, Hjelm NM. 1999. Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet 64:218-224.
24. McGlynn KA, London WT. 2005. Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 19:3-23.
25. Mendy ME, Kaye S, Le Roux E, Kirk GD, Jeng-Barry A, McConkey S, et al. 2008. Application of a novel, rapid, and sensitive oligonucleotide ligation assay for detection of cancer-predicting mutations in the precore and basal core promoter of hepatitis B virus. J Clin Microbiol 46:2723-2730.
26. Mendy ME, Kaye S, van der Sande M, Rayco-Solon P, Waight PA, Shipton D, et al. 2006. Application of real-time PCR to quantify hepatitis B virus DNA in chronic carriers in the Gambia. Virol J 3:23; doi:10.1186/1743-422X-3-23 [Online 4 April 2006].
27. Norder H, Couroucé AM, Coursaget P, Echevarria JM, Lee SD, Mushahwar IK, et al. 2004. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 47:289-309.
28. Norder H, Couroucé AM, Magnius LO. 1992. Molecular basis of hepatitis B virus serotype variations within the four major subtypes. J Gen Virol 73:3141-3145.
29. Norder H, Hammas B, Lee SD, Bile K, Couroucé AM, Mushahwar IK, et al. 1993. Genetic relatedness of hepatitis B viral strains of diverse geographical origin and natural variations in the primary structure of the surface antigen. J Gen Virol 74:1341-48.
30. Sherman M. 2005. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 25:143-154.
31. Szymañska K, Chen JG, Cui Y, Gong YY, Turner PC, Villar S, et al. 2009. TP53 R249S mutations, exposure to aflatoxin, and occurrence of hepatocellular carcinoma in a cohort of chronic hepatitis B virus carriers from Qidong, China. Cancer Epidemiol Biomarkers Prev 18:1638-1643.
32. Szymañska K, Lesi OA, Kirk GD, Sam O, Taniere P, Scoazec JY, et al. 2004. Ser-249TP53 mutation in tumour and plasma DNA of hepatocellular carcinoma patients from a high incidence area in the Gambia, West Africa. Int J Cancer 110:374-379.
33. Turner PC, Mendy M, Whittle H, Fortuin M, Hall AJ, Wild CP. 2000. Hepatitis B infection and aflatoxin biomarker levels in Gambian children. Trop Med Int Health 5:837-841.
34. van der Sande MAB, Waight P, Mendy M, Rayco-Solon P, Hutt P, Fulford T, et al. 2006. Long-term protection against carriage of hepatitis B virus after infant vaccination. J Infect Dis 193:1528-1535.
35. Whittle H, Jaffar S, Wansbrough M, Mendy M, Dumpis U, Collinson A, et al. 2002. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ 325:569; doi:10.1136/bmj.325.7364.569 [Online 14 September 2002].
36. Wild CP, Hall AJ. 2000. Primary prevention of hepatocellular carcinoma in developing countries. Mutat Res 462:381-393.
37. Wild CP, Hudson GJ, Sabbioni G, Chapot B, Hall AJ, Wogan GN, et al. 1992. Dietary intake of aflatoxins and the level of albumin-bound aflatoxin in peripheral blood in the Gambia, West Africa. Cancer Epidemiol Biomarkers Prev 1:229-234.
38. Wild CP, Yin F, Turner PC, Chemin I, Chapot B, Mendy M, et al. 2000. Environmental and genetic determinants of aflatoxin-albumin adducts in the Gambia. Int J Cancer 86:1-7.
39. Yuan JM, Ambinder A, Fan Y, Gao YT, Yu MC, Groopman JD. 2009. Prospective evaluation of hepatitis B 1762T/1764A mutations on hepatocellular carcinoma development in Shanghai, China. Cancer Epidemiol Biomarkers Prev 18:590-594.
40. Zhang SJ, Chen ZX, Jiang KP, Wu WK, Zhang CY, Gu YL. 2006. Effect of seasonal variation on the clinical course of chronic hepatitis B. J Gastroenterol 41:1107-1115.